EGFR and non-small cell lung carcinoma: There are currently dozens of EGFR-targeting drugs for various tumors according to the updated directory of the FDA (11), such as gefitinib for the first-line treatment of non-small cell lung cancer (NSCLC) (12) and erdafitinib, which was first approved for urothelial carcinoma (UC) (13), and the drug catalogue is in continuous iteration (7).